

REMARKS

As per the Ex Parte Quayle Office Action issued March 15, 2004, claims 9, 10, 12, 13, 29, 30, 39 and 40 are allowable.

In the March 15, 2004 Office Action, the Examiner indicated that the application was allowable except for several formal requirements. Specifically, the Examiner objected to the specification in that Figures 4-8 each contain nucleotide sequences that require a sequence identifier which should be listed either in the figures themselves or in each description of the figure. As discussed with the Examiner during the February 12, 2004 telephone conversation, and subsequently noted in our February 12, 2004 Amendment papers, we have reviewed Figures 4-8 and realize that these sequences need to be added to the Sequence Listing filed previously, and given the appropriate sequence identifiers.

To that end, we submit here a **substitute** sequence listing (paper copy and computer readable copy), which is intended to supercede and replace the sequence listing submitted October 25, 2001. This substitute sequence listing differs from the October 25, 2001 sequence listing by the addition of sequences 12-16, which additional sequences correspond to the sequences in Figures 4-8 respectively. The specification has been amended above to list each sequence identifier of Figures 4-8. Along with the substitute sequence listing we submit a Statement to Support Filing and Submission in Accordance with 37 CFR §§ 1.821-1.825.


No new subject matter is introduced by the substitute sequence listing or the amendments to the specification. Entry and consideration of the amended specification and substitute sequence listing are requested.

In summary, all of the Examiner's outstanding rejections and objections have been addressed, and the application is believed to be in allowable form. Notice to that effect is earnestly solicited. No amendment made was related to the statutory requirements of patentability unless expressly stated herein, and no amendment made was for the purpose of narrowing the scope of any claim unless we argued above that such

Hong et al. – Serial No. 09/512,019
Amdt. dated May 12, 2004
Reply to Office Action of March 15, 2004

amendment was made to distinguish over a particular reference or combination of references.

If the Examiner has any questions or would like to make suggestions as to claim language, he is encouraged to contact Marlana K. Titus at (301) 977-7227 (**note that this is a new telephone number**).

By: 

Marlana Titus, Reg. No. 35,843
Tel. No. (301) 977-7227

Nash & Titus, LLC
6005 Riggs Road
Laytonsville, MD 20882